Bastiaan Sallevelt

100 CHAPTER 2.2 Table SI1.4 Continued. STOPP Explanation Clarity rating n=77 E2 (risk of bleeding) 67% E3 (risk of bleeding) 67% G4 (risk of exacerbation of respiratory failure). 67% H2 (risk of exacerbation of hypertension/heart failure) 67% I1 (risk of increased confusion, agitation / risk of urinary retention). 67% J2 (risk of exacerbation of heart failure). 67% J4 (increased risk of recurrence). 67% J5 (risk of endometrial cancer). 67% L3 (risk of non-control of severe pain) 67% B2 (may worsen heart failure). 75% B3 (risk of heart block). 75% B4 (risk of profound hypotension, asystole). 75% B7 (leg elevation and /or compression hosiery usually more appropriate) 75% C1 (increased risk of bleeding, no evidence for increased efficacy). 75% D8 (risk of exacerbation of cognitive impairment). 75% D14 (safer, less toxic antihistamines now widely available). 75% E4 (risk of deterioration in renal function). 75% F4 (no evidence of enhanced iron absorption above these doses). 75% G1 (safer, more effective alternative; risk of adverse effects due to narrow therapeutic index). 75% G2 (unnecessary exposure to long-term side-effects of systemic corticosteroids and effective inhaled therapies are available). 75% H1 (risk of peptic ulcer relapse). 75% H7 (increased risk of myocardial infarction and stroke). 75% H8 (increased risk of peptic ulcer disease). 75% I2 (risk of precipitating recurrent syncope). 75% J1 (risk of prolonged hypoglycaemia). 75% K3 (risk of syncope, falls). 75% B5 (higher risk of side-effects than beta-blockers, digoxin, verapamil or diltiazem) 83% B8 (hypokalaemia, hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic). 83% C2 (risk of recurrent peptic ulcer). 83%